Search
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigationalVictoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine fo...
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hemato...
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[L2932] In July 2025, the FDA expanded approval to include a new pediatric formulation, Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years
Selamectin
go.drugbank.com/drugs/DB11459ExperimentalVet approvedIt also removes 2 types of lungworm in cats and one type of lungworm in dogs. It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological
Gliclazide
go.drugbank.com/drugs/DB01120ApprovedInvestigationalproperties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalFood and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
TGAAC94
go.drugbank.com/drugs/DB06175InvestigationalIn 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA.